Search

Your search keyword '"Kovarova, Lucie"' showing total 35 results
Start Over Author "Kovarova, Lucie"
35 results on '"Kovarova, Lucie"'

16. Review of the Structural and Functional Brain Changes Associated With Chronic Kidney Disease.

Author

MICHNA, Martin, KOVAROVA, Lucie, VALERIANOVA, Anna, MALIKOVA, Hana, WEICHET, Jiri, and MALIK, Jan

Subjects
CHRONIC kidney failure, BRAIN abnormalities, HEMODIALYSIS patients
Abstract

Chronic kidney disease (CKD) leads to profound metabolic and hemodynamic changes, which damage other organs, such as heart and brain. The brain abnormalities and cognitive deficit progress with the severity of the CKD and are mostly expressed among hemodialysis patients. They have great socio-economic impact. In this review, we present the current knowledge of involved mechanisms. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

19. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

Author

Pour Ludek, Michalek Jaroslav, Buchler Tomas, Krejci Marta, Vorlicek Jiri, Kovarova Lucie, Hajek Roman, Almasi Martina, Svachova Hana, Penka Miroslav, Adam Zdenek, and Kralova Dana

Subjects
Adult, Male, medicine.medical_specialty, Angiogenesis, medicine.medical_treatment, Antineoplastic Agents, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Recurrence, Internal medicine, medicine, Humans, Multiple myeloma, Aged, 030304 developmental biology, Aged, 80 and over, 0303 health sciences, Thrombospondin, Chemotherapy, Neovascularization, Pathologic, Hepatocyte Growth Factor, business.industry, Hematology, General Medicine, Middle Aged, medicine.disease, Boronic Acids, 3. Good health, Angiogenesis inhibitor, Endocrinology, medicine.anatomical_structure, Pyrazines, 030220 oncology & carcinogenesis, Female, Hepatocyte growth factor, Bone marrow, Multiple Myeloma, Thrombospondins, business, medicine.drug
Abstract

Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.

Published
2010
Full Text
View/download PDF

35. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Author

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, and Johnsen HE

Subjects
Antibodies, Monoclonal immunology, Antigens, CD analysis, Biomarkers, Tumor analysis, Cell Count instrumentation, Cell Count methods, Chromosome Aberrations, Diagnosis, Differential, Flow Cytometry standards, Humans, Immunophenotyping methods, Immunophenotyping standards, Multiple Myeloma blood, Multiple Myeloma diagnosis, Multiple Myeloma genetics, Neoplasm, Residual, Paraproteinemias blood, Paraproteinemias diagnosis, Paraproteinemias genetics, Paraproteinemias pathology, Plasma Cells chemistry, Plasma Cells pathology, Prognosis, Remission Induction, Flow Cytometry methods, Multiple Myeloma pathology
Abstract

The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results